Trial record 1 of 1 for:    Phenylbutyrate Development for Huntington's Disease
Previous Study | Return to List | Next Study

Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00212316
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : August 15, 2012
HP Therapeutics Foundation
Massachusetts General Hospital
Columbia University
University of Iowa
University of California, San Diego
University of Kansas
University of Alabama at Birmingham
Johns Hopkins University
Information provided by:
University of Rochester

September 19, 2005
September 21, 2005
August 15, 2012
August 2005
Not Provided
Proportion of subjects able to complete treatment (Week 16)
Same as current
Complete list of historical versions of study NCT00212316 on Archive Site
  • Secondary safety and tolerability outcomes at Weeks 1, 4, 5, 10, 16, & 20 include:
  • adverse events,
  • changes in vital signs,
  • and clinical lab assessments.
  • Secondary clinical measures at Weeks 4, 10, 16, and 20 include components of the UHDRS:
  • total motor,
  • Stroop,
  • independence,
  • & total functional capacity.
  • Secondary biological indicators of treatment affects at Weeks 4, 10, 16, & 20 include:
  • markers of neuroprotection (e.g. NAA) via MRS,
  • histone acetylation (levels in WBC; fetal hemoglobin levels in blood),
  • depletion of glutamine,
  • gene expression analyses,
  • and biochemical analyses for pharmacokinetics.
Same as current
Not Provided
Not Provided
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)
Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's Disease
The purpose of this study is to evaluate the safety, tolerability and clinical impact of 15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay the groundwork for possible subsequent trials designed to specifically address its ability to slow or halt the progression of the disease.

Huntington's disease (HD) is an autosomal dominant disorder resulting in selective loss of neurons in the striatum—an area of the brain that controls movement, balance, and walking—and other areas of the brain. The disease is characterized by progressive motor and cognitive decline. There is no cure or even plausible treatment to offset the fatal course of the disease. Therefore, any treatment that ameliorates the disease would be of enormous importance.

The purpose of this double-blind, placebo-controlled study—with open-label follow-up—is to determine the safety and tolerability of 15-grams daily of oral phenylbutyrate in people with HD. The study will enroll 60 individuals. Eligible participants will be initially randomized to receive either phenylbutyrate or the matching placebo for 4 weeks.

After the placebo-controlled phase, all participants will enter the open-label phase to receive phenylbutyrate for 12 weeks. Participants will be followed for one month off phenylbutyrate.

This combination of a short-term double-blind, placebo-controlled phase followed by a longer open-label phase will favor the primary goals of detecting toxicity and intolerability while facilitating recruitment and maximizing number of subjects on study drug.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Huntington's Disease
Drug: sodium phenylbutyrate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
June 2006
Not Provided

Inclusion Criteria:

  • Subjects with clinical diagnosis of HD and family history of HD or a CAG repeat expansion greater than or equal to 37
  • Subjects in stage I or II of illness (TFC greater than or equal to 7)
  • Subjects must be ambulatory and not requiring skilled nursing care
  • Age of 18 years or older
  • Women of childbearing potential (i.e., those not postmenopausal or surgically sterile) must confirm to the best of their knowledge that they are not pregnant or plan to get pregnant
  • Women of childbearing potential must have negative pregnancy test, be non-lactating and use adequate contraception methods, such as oral birth control pills plus a barrier method (i.e. condoms, diaphragm) or IUD during their participation in the study
  • Subjects currently taking psychotropic medications (including antidepressants and neuroleptics) must be on stable dosages for at least 4 weeks prior to baseline visit and should be maintained on constant dosage throughout the study
  • Subjects must be capable of providing informed consent and complying with trial procedures
  • Subjects must be able to take oral medication, a person willing and able to serve as an informant and provide information about the daily dosing of study medication

Exclusion Criteria:

  • Exposure to phenylbutyrate, valproic acid, probenecid, known HDAC inhibitors or other transcriptionally active compounds within 3 months (90 days) prior to the baseline visit
  • History of known sensitivity or intolerability to phenylbutyrate, sodium butyrate or sodium acetate
  • Existence of a known malignancy that might require treatment during the course of this study
  • Exposure to any investigational drug within 30 days of the baseline visit
  • Subjects with underlying hematologic, hepatic or renal disease; screening white blood cell (WBC) count less than 3,800/mm3, screening creatinine greater than 2.0 or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal
  • Clinical evidence of unstable medical illness in the investigator's judgment
  • Clinical illness that requires use of warfarin (Coumadin)
  • Unstable psychiatric illness defined as psychosis (hallucinations or delusions) untreated major depression or plan for suicide within 90 days of the baseline visit
  • Current or history of substance (alcohol or drug) abuse within 1 year of the baseline visit
  • Pregnant women or women who are currently breast-feeding
  • History of heart failure or other conditions that might be exacerbated by sodium loading
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
University of Rochester
  • HP Therapeutics Foundation
  • Massachusetts General Hospital
  • Columbia University
  • University of Iowa
  • University of California, San Diego
  • University of Kansas
  • University of Alabama at Birmingham
  • Johns Hopkins University
Principal Investigator: Steven M. Hersch, MD, PhD Co-Chair, Huntington Study Group, Massachusetts General Hospital
Principal Investigator: Karl Kieburtz, MD, MPH Director, Clinical Trials Coordination Center, University of Rochester
University of Rochester
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP